



Veracyte to Participate in Upcoming Investor Conferences

July 28, 2026

SOUTH SAN FRANCISCO, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- [Veracyte, Inc.](#) (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will be participating in the following investor conferences:

- **Canaccord Genuity 46th Annual Growth Conference – Boston, MA**
Fireside chat on Tuesday, Aug 11th at 10:30 a.m. Eastern Time
- **Morgan Stanley 24th Annual Global Healthcare Conference – New York, NY**
Fireside chat on Tuesday, Sep 15th at 5:35 p.m. Eastern Time

Live audio webcasts of the company's presentations will be available by visiting Veracyte's website at <http://investor.veracyte.com/events-presentations>. Replays of the webcasts will be available for 90 days after each live presentation broadcast.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company's molecular tests assess the unique biology of each patient's tumor to help clinicians answer essential questions about cancer care. [Veracyte's Diagnostics Platform](#) combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued [innovation and pipeline development](#). The company's portfolio includes the [Afirma® Genomic Sequencing Classifier test](#), [Decipher® Bladder Genomic Classifier test](#), [Decipher® Prostate Genomic Classifier test](#), [Prosigna® Breast Risk of Recurrence test](#), and the [TrueMRD™ Monitoring Test for MIBC](#). For more information, visit Veracyte's [website](#) or follow the company on [LinkedIn](#) or [X \(Twitter\)](#).

Investors

Kelly Gura
investors@veracyte.com

Media

Molly Cornbleet
media@veracyte.com
+1-650-351-8780